FDA-cleared profile

uMI Panvivo (uMI Panvivo); uMI Panvivo (uMI Panvivo S)

Shanghai United Imaging Healthcare Co.,Ltd. · PET/SPECT/Nuclear Medicine · FDA-cleared (510(k))

Authorized purpose: The uMI Panvivo PET/CT system provides anatomical and functional images. PET depicts the distribution of approved radiopharmaceuticals and CT provides diagnostic tomographic and photon-attenuation information. The FDA indication describes qualified-professional use for detection, localization, evaluation, diagnosis, staging, restaging, monitoring, and follow-up in oncology, infection and inflammation, neurology, and other labeled workflows, plus radiotherapy planning, interventional radiology, and protocol-constrained low-dose lung-cancer screening.

Clinical role
PET or PET/CT acquisition, reconstruction, attenuation correction, fusion, visualization, and quantitative review.
Images and patients
PET/SPECT/Nuclear Medicine · Whole body and regional anatomy represented in PET/CT studies
Key limitation
Keep in mind: Radiopharmaceutical, scan range, dose, acquisition, reconstruction, patient, and screening-protocol requirements apply. The screening statement is not a universal screening recommendation, and interpretation remains with qualified medical professionals.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: The uMI Panvivo PET/CT system provides anatomical and functional images. PET depicts the distribution of approved radiopharmaceuticals and CT provides diagnostic tomographic and photon-attenuation information. The FDA indication describes qualified-professional use for detection, localization, evaluation, diagnosis, staging, restaging, monitoring, and follow-up in oncology, infection and inflammation, neurology, and other labeled workflows, plus radiotherapy planning, interventional radiology, and protocol-constrained low-dose lung-cancer screening.
  • Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Whole body and regional anatomy represented in PET/CT studies Input: Supported PET emission data, CT transmission data, radiopharmaceutical and patient information, and acquisition metadata.
  • Who uses it?Intended users: Qualified nuclear-medicine physicians, radiologists, technologists, and trained PET/CT professionals.
  • What does the software produce?Output: PET, CT, fused, attenuation-corrected, quantitative, and treatment-planning images for qualified interpretation.
  • What is its most important limitation?Key limitation: Radiopharmaceutical, scan range, dose, acquisition, reconstruction, patient, and screening-protocol requirements apply. The screening statement is not a universal screening recommendation, and interpretation remains with qualified medical professionals.

Clinical takeaway. Clinical role: The uMI Panvivo PET/CT system provides anatomical and functional images. PET depicts the distribution of approved radiopharmaceuticals and CT provides diagnostic tomographic and photon-attenuation information. The FDA indication describes qualified-professional use for detection, localization, evaluation, diagnosis, staging, restaging, monitoring, and follow-up in oncology, infection and inflammation, neurology, and other labeled workflows, plus radiotherapy planning, interventional radiology, and protocol-constrained low-dose lung-cancer screening.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical testing for uMI Panvivo to verify that the device met all design specifications, with claimed conformance to listed standards and guidance, including NEMA NU 2-2018 for PET performance measurements. Sample clinical images were reviewed by U.S. board-certified radiologist, showing image quality sufficient for diagnostic use. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
The uMI Panvivo PET/CT system provides anatomical and functional images. PET depicts the distribution of approved radiopharmaceuticals and CT provides diagnostic tomographic and photon-attenuation information. The FDA indication describes qualified-professional use for detection, localization, evaluation, diagnosis, staging, restaging, monitoring, and follow-up in oncology, infection and inflammation, neurology, and other labeled workflows, plus radiotherapy planning, interventional radiology, and protocol-constrained low-dose lung-cancer screening.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
PET or PET/CT acquisition, reconstruction, attenuation correction, fusion, visualization, and quantitative review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported PET emission data, CT transmission data, radiopharmaceutical and patient information, and acquisition metadata.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
PET, CT, fused, attenuation-corrected, quantitative, and treatment-planning images for qualified interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital or outpatient molecular-imaging departments using the exact PET or PET/CT configuration and radiopharmaceutical workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified nuclear-medicine physicians, radiologists, technologists, and trained PET/CT professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Radiopharmaceutical, scan range, dose, acquisition, reconstruction, patient, and screening-protocol requirements apply. The screening statement is not a universal screening recommendation, and interpretation remains with qualified medical professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports non-clinical testing for uMI Panvivo to verify that the device met all design specifications, with claimed conformance to listed standards and guidance, including NEMA NU 2-2018 for PET performance measurements. Sample clinical images were reviewed by U.S. board-certified radiologist, showing image quality sufficient for diagnostic use. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-clinical testing was conducted for uMI Panvivo to verify that the proposed device met all design specifications as it is Substantially Equivalent (SE) to the predicate device." … "UNITED IMAGING HEALTHCARE claims conformance to the following standards and guidance:". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical testing for uMI Panvivo to verify that the device met all design specifications, with claimed conformance to listed standards and guidance, including NEMA NU 2-2018 for PET performance measurements. Sample clinical images were reviewed by U.S. board-certified radiologist, showing image quality sufficient for diagnostic use. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-clinical testing was conducted for uMI Panvivo to verify that the proposed device met all design specifications as it is Substantially Equivalent (SE) to the predicate device." … "UNITED IMAGING HEALTHCARE claims conformance to the following standards and guidance:". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K243538 FDA decision evidence for uMI Panvivo (uMI Panvivo); uMI Panvivo (uMI Panvivo S)

  • DesignFDA 510(k) substantial-equivalence review of the exact submission, device description, indications, and verification or validation documentation.
  • PopulationWhole body and regional anatomy represented in PET/CT studies
  • Scopeexact submission
  • Tested versionuMI Panvivo and uMI Panvivo S
  • IndependenceSponsor or vendor study

K243538

The FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K243538 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, surgical, or diagnostic service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported PET emission data, CT transmission data, radiopharmaceutical and patient information, and acquisition metadata.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K243538: uMI Panvivo (uMI Panvivo); uMI Panvivo (uMI Panvivo S)

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, archive, and downtime locally.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 ·

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: PET, CT, fused, attenuation-corrected, quantitative, and treatment-planning images for qualified interpretation.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K243538: uMI Panvivo (uMI Panvivo); uMI Panvivo (uMI Panvivo S)

  5. Viewer/worklist/report

    Unresolved route: PET, CT, fused, attenuation-corrected, quantitative, and treatment-planning images for qualified interpretation.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K243538: uMI Panvivo (uMI Panvivo); uMI Panvivo (uMI Panvivo S)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Security
United Imaging Healthcare's cybersecurity page lists a secure development lifecycle and controls: firewall, encrypted connections, OS hardening, antivirus, patches, authentication, audit log, disk and transmission encryption. Company-level, not release-specific.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Training
Only qualified nuclear-medicine physicians, radiologists, technologists, and trained pet/ct professionals should operate or interpret this product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Radiopharmaceutical, scan range, dose, acquisition, reconstruction, patient, and screening-protocol requirements apply. The screening statement is not a universal screening recommendation, and interpretation remains with qualified medical professionals.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K243538 before acceptance. Later family features are not evidence for this exact submission.

exact submission · checked 2026-09-04

Interoperability acceptance

The exact FDA material does not establish a complete interoperability contract. Establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Deployment and security qualification

The exact FDA material does not establish hosting, deployment topology, availability, upgrade path, or service responsibility. Obtain site-specific evidence before procurement.

exact submission · checked 2026-09-04

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Radiopharmaceutical, scan range, dose, acquisition, reconstruction, patient, and screening-protocol requirements apply. The screening statement is not a universal screening recommendation, and interpretation remains with qualified medical professionals.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs. No exact-product price was found.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Radiopharmaceutical, scan range, dose, acquisition, reconstruction, patient, and screening-protocol requirements apply. The screening statement is not a universal screening recommendation, and interpretation remains with qualified medical professionals.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243538
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
PET/SPECT/Nuclear Medicine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Whole body and regional anatomy represented in PET/CT studies
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-12-12
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
33Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor documentation, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or approved configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, archive, and downtime locally.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K243538: uMI Panvivo (uMI Panvivo); uMI Panvivo (uMI Panvivo S)

    U.S. Food and Drug Administration - Published 2024-12-12 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. United Imaging Healthcare Cybersecurity

    United Imaging Healthcare - Accessed 2026-10-25

    Scope: security

Research history

  1. K243538 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K241596

uMI Panvivo

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: The uMI Panvivo is a PET/CT system for anatomical and functional images. PET provides distribution information for approved radiopharmaceuticals and CT provides diagnostic tomographic anatomy and photon attenuation information. The FDA material describes qualified-professional assessment of metabolic and physiologic functions and labeled detection, diagnosis, staging, monitoring, follow-up, radiotherapy-planning, and interventional workflows.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body and regional anatomy represented in PET/CT studies
Decision
2024-08-15
FDA-cleared K233677

Biograph VK10

Siemens Medical Solutions USA, Inc.

Authorized purpose: The Biograph VK10 combines X-ray CT and PET to register and fuse anatomic and physiologic information, supports independent CT or PET imaging, and aids trained professionals in detecting, localizing, diagnosing, staging, and restaging disease, lesions, tumors, and organ function; the CT may also support radiotherapy planning, interventional procedures, and low-dose lung-cancer screening in high-risk populations.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, cardiovascular, neurological, oncologic, and organ-function imaging
Decision
2024-01-12
FDA-cleared K231833

Biograph Vision.X and Biograph Vision.X Edge

Siemens Medical Solutions USA, Inc.

Authorized purpose: The Biograph Vision.X and Biograph Vision.X Edge combine X-ray CT and PET to register and fuse anatomic and physiologic information, support independent CT or PET imaging, aid trained professionals in detecting, localizing, diagnosing, staging, and restaging disease, lesions, tumors, and organ function, and support radiotherapy planning, interventional procedures, and low-dose lung-cancer screening in high-risk populations.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, cardiovascular, neurological, oncologic, and organ-function imaging
Decision
2023-07-13
FDA-cleared K211764

Vereos PET/CT

Philips Medical Systems Nederland B.V.

Authorized purpose: Vereos PET/CT detects, localizes, diagnoses, stages, restages, and follows treatment response in oncology, cardiology, and neurology and can provide diagnostic CT and radiotherapy-planning support; optional PET Adaptive Reconstruction is an AI-powered image-reconstruction function.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2021-08-06

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history